The firm said it plans to sign between five and 10 additional biopharma collaborations in fiscal year 2020, some with milestone and royalty payment structures.
The firm reported full year revenues of $54.4 million and fiscal Q4 revenues of $15.7 million, beating the consensus Wall Street estimates for both.
Two new grants are helping the company develop its SHERLOCK and INSPECTR technologies as the basis for creating innovative diagnostics.
Last week's SynBioBeta conference was indicative of the high degree of interest in the synthetic bio space from omics research tool vendors.
The San Diego-based DNA synthesis firm this week announced $12.2 million in Series A funding, but has plans to expand the round.
The Boston-based synthetic biology firm said it will use the funds to grow its cell programing platform, which it will make available to startups.
In Nature this week: synthetic Escherichia coli genome with fewer codons, and more.
During the second quarter of fiscal 2019, the firm took orders for genes, libraries, and oligonucleotide pools from about 780 customers.
The Economist explores potential uses of synthetic biology to alter what proteins are produced.
In Science this week: the synthetic genetic system hachimoji, and more.
ScienceInsider reports that rude and unprofessional paper reviewers are common and can have harmful effects.
The US Senate has confirmed Stephen Hahn as the next commissioner of the Food and Drug Administration, according to the New York Times.
CNBC reports Apple is partnering with Color Genomics to offer its employees free DNA screening for disease.
In Science this week: researchers use CRISPR tool to find gut microbiome molecules involved in immunity, and more.
